Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients

International Journal of Cancer

Volumn 135, Issue 11, 2014, Pages 2727-2734

  Warta, Rolf ^a,b   Herold Mende, Christel ^a,b   Chaisaingmongkol, Jittiporn ^c   Popanda, Odilia ^c   Mock, Andreas ^a   Mogler, Carolin ^b,c   Osswald, Florian ^a   Herpel, Esther ^b,c   Küstner, Sabine ^a   Eckstein, Volker ^b   Plass, Christoph ^c   Plinkert, Peter ^a   Schmezer, Peter ^c   Dyckhoff, Gerhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

CSPG4 methylation and expression; HNSCC; Survival

Indexed keywords

CHONDROITIN SULFATE PROTEOGLYCAN 4; PROTEOCHONDROITIN SULFATE; UNCLASSIFIED DRUG; CSPG4 PROTEIN, HUMAN; MEMBRANE PROTEIN; MESSENGER RNA;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CPG ISLAND; FLUORESCENCE ACTIVATED CELL SORTING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CASE CONTROL STUDY; COMPARATIVE STUDY; DNA METHYLATION; ENZYME IMMUNOASSAY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR CELL CULTURE; YOUNG ADULT;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHONDROITIN SULFATE PROTEOGLYCANS; CPG ISLANDS; DNA METHYLATION; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84921353803     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28906     Document Type: Article

References (33)

1. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143-54.
2. Chaisaingmongkol J, Popanda O, Warta R, et al. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma. Oncogene 2012;31:5108-16.
3. Morgan AC, Jr, Galloway DR, Reisfeld RA. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma 1981;1:27-36.
4. Wang X, Osada T, Wang Y, et al. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 2010;102:1496-512.
5. Wang X, Katayama A, Wang Y, et al. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res 2011;71:7410-22.
6. Zeppernick F, Ahmadi R, Campos B, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008;14:123-9.
7. Karram K, Goebbels S, Schwab M, et al. NG2-expressing cells in the nervous system revealed by the NG2-EYFP-knockin mouse. Genesis 2008;46: 743-57.
8. Svendsen A, Verhoeff JJC, Immervoll H, et al. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol 2011; 122:495-510.
9. Benassi MS, Pazzaglia L, Chiechi A, et al. NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J Orthop Res 2009; 27:135-40.
10. Al-Mayhani MTF, Grenfell R, Narita M, et al. NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. Neurooncology 2011;13: 830-45.
11. Rivera Z, Ferrone S, Wang X, et al. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res 2012; 18:5352-63.
12. Price MA, Colvin Wanshura LE, Yang J, et al. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res 2011;24:1148-57.
13. Begum S, Cao D, Gillison M, et al. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 2005;11:5694-9.
14. Bussu F, Paludetti G, Almadori G, et al. Comparison of total laryngectomy with surgical (cricohyoidopexy) and nonsurgical organ-preservation modalities in advanced laryngeal squamous cell carcinomas: a multicenter retrospective analysis. Head Neck 2013;35:554-61.
15. Vasvari GP, Dyckhoff G, Kashfi F, et al. Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. Int J Cancer 2007;121:1697-704.
16. Freier K, Hofele C, Knoepfle K, et al. Cytogenetic characterization of head and neck squamous cell carcinoma cell lines as model systems for the functional analyses of tumor-associated genes. J Oral Pathol Med 2010;39:382-9.
17. Campos B, Zeng L, Daotrong PH, et al. Expression and regulation of AC133 and CD133 in glioblastoma. Glia 2011;59:1974-86.
18. Lohr J, Ratliff T, Huppertz A, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumorderived TGF-b. Clin Cancer Res 2011;17:4296-308.
19. Herold-Mende C, Mueller MM, Bonsanto MM, et al. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 2002;98:362-9.
20. Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30:207-10.
21. Luo W, Wang X, Kageshita T, et al. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene 2006;25: 2873-84.
22. Wu H, Caffo B, Jaffee HA, et al. Redefining CpG islands using hidden Markov models. Biostatistics 2010;11:499-514.
23. Whang YM, Choi EJ, Seo JH, et al. Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor beta expression in head and neck squamous carcinoma (HNSCC) cells. Cancer Chemother Pharmacol 2005;56: 543-55.
24. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 2000;25:269-77.
25. Wade PA, Gegonne A, Jones PL, et al. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 1999;23:62-6.
26. Zuo C, Ai L, Ratliff P, et al. O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:967-75.
27. Marsit CJ, Posner MR, McClean MD, et al. Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma. Cancer 2008;113: 1566-71.
28. Legg J, Jensen UB, Broad S, et al. Role of melanoma chondroitin sulphate proteoglycan in patterning stem cells in human interfollicular epidermis. Development 2003;130:6049-63.
29. Jensen KB, Jones J, Watt FM. A stem cell gene expression profile of human squamous cell carcinomas. Cancer Lett 2008;272:23-31.
30. Yang J, Price MA, Li GY, et al. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-tomesenchymal transition. Cancer Res 2009;69: 7538-47.
31. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
32. Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 2011;118:1472-80.
33. De Bruyn M, Rybczynska AA, Wei Y, et al. Melanoma-associated chondroitin sulfate proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer 2010;9:301.